Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Daniele Generali, Giuseppina Barbieri et al.|Frontiers in Oncology|2021Cited by 19
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast CancerMarianna Sirico, Daniele Generali, Ottavia Bernocchi et al.|Cancers|2020Cited by 9
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET studySilvia Paola Corona, Daniele Generali, Fabiola Giudici et al.|Oncotarget|2020Cited by 8
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving OlaparibFrancesco Schettini, Daniele Generali, Maria Valeria De Bonis et al.|Scientific Reports|2023Cited by 6
Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET studySilvia Paola Corona, Daniele Generali, Fabiola Giudici et al.|Oncotarget|2022Cited by 0